Title : A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.

Pub. Date : 2007 Mar 1

PMID : 17332297






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Pharmacokinetic analysis at 1.3 mg/m(2) revealed a clearance of 11 mL/h/m(2), a central volume of distribution of 6.7 L/m(2), and a terminal half-life of 12.6 h. NF-kappaB activity was examined in five patients and was noted to transiently increase and then decrease 4- to 6-fold by 24 h following bortezomib in two patients. Bortezomib nuclear factor kappa B subunit 1 Homo sapiens
2 Although bortezomib treatment inhibited NF-kappaB activity, bortezomib had little activity as a single agent in this population. Bortezomib nuclear factor kappa B subunit 1 Homo sapiens